Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in the United States, Canada, and internationally. More Details
Adequate balance sheet with limited growth.
Share Price & News
How has Invitae's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NVTA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: NVTA exceeded the US Biotechs industry which returned 33.3% over the past year.
Return vs Market: NVTA exceeded the US Market which returned 10.9% over the past year.
Price Volatility Vs. Market
How volatile is Invitae's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 hours ago | Simply Wall StInvitae's (NYSE:NVTA) Wonderful 477% Share Price Increase Shows How Capitalism Can Build Wealth
1 month ago | Simply Wall StHave Insiders Sold Invitae Corporation (NYSE:NVTA) Shares Recently?
1 month ago | Simply Wall StHow Much Are Invitae Corporation (NYSE:NVTA) Insiders Taking Off The Table?
Is Invitae undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NVTA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NVTA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NVTA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: NVTA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NVTA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NVTA is overvalued based on its PB Ratio (12.1x) compared to the US Biotechs industry average (3.2x).
How is Invitae forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NVTA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NVTA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NVTA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NVTA's revenue (36.1% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: NVTA's revenue (36.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NVTA is forecast to be unprofitable in 3 years.
How has Invitae performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NVTA is currently unprofitable.
Growing Profit Margin: NVTA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NVTA is unprofitable, and losses have increased over the past 5 years at a rate of 29.2% per year.
Accelerating Growth: Unable to compare NVTA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NVTA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: NVTA has a negative Return on Equity (-90.6%), as it is currently unprofitable.
How is Invitae's financial position?
Financial Position Analysis
Short Term Liabilities: NVTA's short term assets ($471.1M) exceed its short term liabilities ($126.9M).
Long Term Liabilities: NVTA's short term assets ($471.1M) exceed its long term liabilities ($378.8M).
Debt to Equity History and Analysis
Debt Level: NVTA's debt to equity ratio (59.5%) is considered high.
Reducing Debt: NVTA's debt to equity ratio has increased from 0.06% to 59.5% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NVTA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NVTA has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 20.1% each year.
What is Invitae current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NVTA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NVTA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NVTA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NVTA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NVTA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sean George (46 yo)
Dr. Sean Emerson George, Ph.D. is the Co-Founder of InVitae Corporation and has been its Chief Executive Officer since January 9, 2017, President since August 2012 and its Chairman since September 1, 2019 ...
CEO Compensation Analysis
Compensation vs Market: Sean's total compensation ($USD5.49M) is about average for companies of similar size in the US market ($USD7.46M).
Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.
|Chief Financial Officer||3.25yrs||US$3.05m||0.050% |
|Chief Medical Officer||5.08yrs||US$2.99m||0.035% |
|Chief Policy Officer||0.17yr||US$3.05m||0.0086% |
|Chief Commercial Officer||3.92yrs||US$3.03m||0.055% |
|Co-Founder||no data||no data||no data|
|Co-Founder||no data||no data||no data|
|Chief Operating Officer||0.25yr||no data||no data|
|Chief Accounting Officer||0.33yr||no data||0.0021% |
|Chief Technology Officer||0.67yr||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|General Counsel||3.67yrs||no data||0.055% |
Experienced Management: NVTA's management team is considered experienced (3.3 years average tenure).
|Independent Director||10yrs||US$195.18k||0% |
|Independent Director||4.83yrs||US$190.18k||0% |
|Independent Director||8.5yrs||US$195.18k||0.022% |
|Independent Director||2yrs||US$141.06k||0% |
|Director||no data||no data||no data|
Experienced Board: NVTA's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NVTA insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 38.5%.
Invitae Corporation's company bio, employee growth, exchange listings and data sources
- Name: Invitae Corporation
- Ticker: NVTA
- Exchange: NYSE
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$5.629b
- Shares outstanding: 131.79m
- Website: https://www.invitae.com
Number of Employees
- Invitae Corporation
- 1400 16th Street
- San Francisco
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|NVTA||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Feb 2015|
|IV8||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2015|
|0JDB||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Feb 2015|
Invitae Corporation, a medical genetics company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their pa ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/25 05:37|
|End of Day Share Price||2020/09/24 00:00|